Literature DB >> 14727049

[Activated protein C. Inevitable in sepsis?].

M Max1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14727049     DOI： 10.1007/s00101-003-0592-x

Source DB:  PubMed          Journal:  Anaesthesist        ISSN： 0003-2417            Impact factor:   1.041


× No keyword cloud information.
  19 in total

Review 1.  Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?

Authors:  C T Esmon
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

2.  Keep in contact: the role of the contact system in infection and sepsis.

Authors:  M Levi
Journal:  Crit Care Med       Date:  2000-11       Impact factor: 7.598

3.  Meta-analysis of acute lung injury and acute respiratory distress syndrome trials testing low tidal volumes.

Authors:  Peter Q Eichacker; Eric P Gerstenberger; Steven M Banks; Xizhong Cui; Charles Natanson
Journal:  Am J Respir Crit Care Med       Date:  2002-08-28       Impact factor: 21.405

4.  Risks and benefits of activated protein C treatment for severe sepsis.

Authors:  H Shaw Warren; Anthony F Suffredini; Peter Q Eichacker; Robert S Munford
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

5.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

6.  Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

Authors:  B L Warren; A Eid; P Singer; S S Pillay; P Carl; I Novak; P Chalupa; A Atherstone; I Pénzes; A Kübler; S Knaub; H O Keinecke; H Heinrichs; F Schindel; M Juers; R C Bone; S M Opal
Journal:  JAMA       Date:  2001-10-17       Impact factor: 56.272

Review 7.  Pathophysiology of disseminated intravascular coagulation in sepsis.

Authors:  H ten Cate
Journal:  Crit Care Med       Date:  2000-09       Impact factor: 7.598

8.  Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

Authors:  E Abraham; K Reinhart; P Svoboda; A Seibert; D Olthoff; A Dal Nogare; R Postier; G Hempelmann; T Butler; E Martin; C Zwingelstein; S Percell; V Shu; A Leighton; A A Creasey
Journal:  Crit Care Med       Date:  2001-11       Impact factor: 7.598

9.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

Authors:  Djillali Annane; Véronique Sébille; Claire Charpentier; Pierre-Edouard Bollaert; Bruno François; Jean-Michel Korach; Gilles Capellier; Yves Cohen; Elie Azoulay; Gilles Troché; Philippe Chaumet-Riffaud; Philippe Chaumet-Riffaut; Eric Bellissant
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

10.  Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy.

Authors:  Jean-Pierre Sollet; Gary E Garber
Journal:  Am J Surg       Date:  2002-12       Impact factor: 2.565
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.